Chronic Postsurgical or Posttraumatic Pain

Chronic postsurgical pain (CPSP) is defined by the International Association for the Study of Pain (IASP) as pain that develops or increases in intensity after a surgical procedure, persists beyond the normal tissue-healing period (typically ≥3 months), and is localised to the surgical site, a referred area, or a remote dermatome. Chronic posttraumatic pain follows non-surgical injuries (fractures, burns, soft-tissue trauma, road traffic collisions) and shares overlapping mechanisms. Together, these syndromes represent one of the most common causes of chronic non-cancer pain in Australia.

CPSP is not a single entity but a spectrum ranging from nociceptive-inflammatory pain persisting beyond expected healing, through mixed nociceptive–neuropathic states, to predominantly neuropathic syndromes driven by peripheral and central sensitisation. Postamputation pain — encompassing both residual limb pain and phantom limb pain — occupies the severe end of this spectrum and is frequently refractory to simple analgesia.

Australian Epidemiology

• Approximately 2.5 million surgical procedures are performed annually in Australia (AIHW, 2023). CPSP prevalence varies by procedure: 10–12% after caesarean section, 20–30% after inguinal hernia repair, 25–40% after thoracotomy, 30–50% after breast surgery, and 30–60% after amputation.
• The Australian Institute of Health and Welfare estimates that chronic pain affects approximately 3.4 million Australians (16%), with postsurgical and posttraumatic origins accounting for a significant proportion.
• Inguinal hernia repair is one of the most common operations in Australia; chronic groin pain affects 10–12% of patients at 1 year, with 2–5% experiencing severe pain affecting daily function.
• Approximately 5,000 major amputations are performed annually in Australia, predominantly for peripheral vascular disease and diabetes. Chronic amputation-related pain affects 50–80% of this population.
• Road trauma and workplace injuries contribute substantially to chronic posttraumatic pain. ReturnSafe and WorkSafe data indicate that persistent pain is the primary barrier to return-to-work in 30–40% of musculoskeletal injury claims.
• Burns injuries affect approximately 50,000 Australians annually; chronic pain after burns occurs in 30–50% of cases, often with significant neuropathic features.
• The economic burden of chronic pain in Australia exceeds 9 billion per year (Deloitte Access Economics, 2019), with postsurgical pain representing a major contributor through healthcare costs, lost productivity, and informal carer burden.

The transition from acute to chronic pain involves complex neurobiological processes. Understanding these mechanisms guides rational pharmacotherapy and helps explain why purely opioid-based approaches are ineffective for established CPSP.

Peripheral Sensitisation

Tissue injury during surgery or trauma releases inflammatory mediators (bradykinin, prostaglandins, histamine, cytokines — TNF-α, IL-1β, IL-6) that lower activation thresholds of nociceptors. Ongoing inflammation and fibrosis at the surgical site maintain peripheral nociceptive input. Nerve injury — inevitable in many surgical approaches — triggers ectopic discharge from neuromas and dorsal root ganglia, producing spontaneous pain and allodynia.

Central Sensitisation

Persistent nociceptive barrage activates NMDA receptors in the dorsal horn, wind-up phenomena, and long-term potentiation of synaptic transmission. Descending facilitation from the rostral ventromedial medulla amplifies spinal cord excitability, while descending inhibition (serotonergic and noradrenergic pathways from the periaqueductal grey and locus coeruleus) is downregulated. These processes explain the spread of pain beyond the original injury site and the development of widespread mechanical hyperalgesia.

Neuroplastic Changes

Cortical reorganisation — particularly in the primary somatosensory cortex — is well documented in phantom limb pain and contributes to the persistence and quality of the pain experience. Mirror therapy and graded motor imagery target this cortical maladaptation.

Genetic and Psychological Modulators

Genetic polymorphisms in COMT, GCH1, and SCN9A influence individual susceptibility to CPSP. Pre-operative psychological factors — anxiety, depression, pain catastrophising, and fear-avoidance — are among the strongest predictors of CPSP development, mediated through enhanced central sensitisation and altered stress-hormone responses.

Chronic postsurgical pain is among the most common iatrogenic chronic pain syndromes. It is procedure-dependent, with risk varying according to the degree of nerve manipulation, pre-operative pain, and psychological vulnerability.

High-Risk Procedures

Risk Factors for CPSP

Preventive Strategies (Pre-emptive Analgesia)

• Administer multimodal analgesia before surgical incision: paracetamol 1 g PO, celecoxib 200–400 mg PO (if no contraindication), gabapentin 300–600 mg PO (pre-anaesthesia), and dexamethasone 8 mg IV.
• Regional anaesthesia (peripheral nerve blocks, epidural, or wound infiltration with long-acting local anaesthetic — liposomal bupivacaine where available) is strongly associated with reduced CPSP incidence.
• Ketamine infusion (subanaesthetic dose, 0.1–0.3 mg/kg/hr intraoperatively) may reduce CPSP at 3 months in high-risk patients (evidence level B).
• Pre-operative psychological screening using the Pain Catastrophising Scale (PCS) and brief CBT-based interventions reduce CPSP risk.

Postamputation pain encompasses two distinct but frequently coexisting conditions: residual limb (stump) pain and phantom limb pain. Both have a strong neuropathic component, and both are underrecognised and undertreated in Australian amputee populations.

Residual Limb Pain

• Affects 50–70% of amputees; arises from the remaining stump tissue.
• Causes include neuroma formation (most common), ill-fitting prosthesis, skin breakdown, osteomyelitis, heterotopic ossification, ischaemia, and complex regional pain syndrome (CRPS).
• Neuroma pain is typically lancinating, localised to a specific trigger point (Tinel sign positive), and worsened by prosthetic use or pressure.
• Management: desensitisation programmes, prosthetic optimisation, neuroma-targeted pharmacotherapy (TCAs, gabapentinoids), ultrasound-guided nerve blocks, and surgical neuroma revision as a last resort.

Risk Factors Specific to Postamputation Pain

• Pre-amputation pain (duration and intensity)
• Traumatic vs surgical amputation (traumatic carries higher risk)
• Upper limb amputation (higher CPSP rates than lower limb)
• Phantom sensations in the first 24 hours post-amputation predict later phantom pain
• Psychological distress, depression, and PTSD (especially in traumatic amputation)

Phantom limb pain (PLP) is the perception of pain in the amputated body part that cannot be attributed to ongoing peripheral pathology in the residual limb. It is distinct from phantom sensations (non-painful awareness of the missing limb, experienced by up to 90% of amputees) and must be differentiated from residual limb pain, although the two frequently coexist.

Epidemiology

• PLP prevalence: 40–80% of amputees within the first 2 years; 5–10% develop severe, refractory pain.
• Onset: typically within the first week post-amputation (60–80%), but can be delayed by months or years.
• Natural history: tends to decrease in frequency and intensity over the first 2 years in approximately 50% of patients; however, the remaining 50% experience persistent or worsening symptoms.

Pathophysiology

PLP involves multiple levels of the neuraxis:

• Peripheral: Neuroma formation with ectopic sodium channel expression and spontaneous C-fibre and Aβ-fibre discharge.
• Spinal: Loss of afferent input leads to dorsal horn reorganisation, sprouting of Aβ-fibres into lamina II (normally nociceptive territory), and upregulation of spinal NMDA and substance P receptors.
• Supraspinal/cortical: Deafferentation of the somatotopic map in the primary somatosensory cortex (S1) causes cortical reorganisation. Adjacent body regions "invade" the deafferented cortical territory. The degree of cortical reorganisation correlates positively with phantom pain intensity — this is the basis for mirror therapy.
• Descending modulation: Reduced descending inhibitory serotonergic and noradrenergic activity; enhanced descending facilitation from the brainstem.

Clinical Features

• Quality: burning, shooting, cramping, throbbing, stabbing, or tingling; often described as the missing limb being held in an abnormal, cramped position.
• Location: typically the most distal part of the missing limb (toes, foot, fingers).
• Triggers: cold weather, emotional stress, fatigue, pressure on the residual limb, constipation, and phantom limb postural changes.
• Temporal pattern: often paroxysmal with intervening pain-free periods; may evolve to continuous pain.

Management of Phantom Limb Pain

Chronic posttraumatic pain follows non-surgical injuries including fractures, soft-tissue injuries, burns, road traffic collisions, workplace injuries, and assault. The transition from acute to chronic posttraumatic pain is mediated by the same peripheral and central sensitisation mechanisms as CPSP, but is compounded by the psychological impact of trauma, particularly when injury is sudden, violent, or associated with PTSD.

Common Posttraumatic Pain Syndromes

Complex Regional Pain Syndrome (CRPS)

CRPS deserves special mention as one of the most debilitating posttraumatic pain conditions. The Budapest criteria (2003, validated 2010) are the accepted diagnostic standard.

• CRPS Type I (reflex sympathetic dystrophy): follows minor tissue injury without identifiable nerve lesion.
• CRPS Type II (causalgia): follows identifiable nerve injury.
• Early physiotherapy and functional restoration are the cornerstones of treatment — immobilisation worsens outcomes.
• Pharmacotherapy: gabapentinoids, low-dose naltrexone, bisphosphonates (for bone oedema), topical agents; opioids are generally ineffective for CRPS.
• Interventional: sympathetic blocks, spinal cord stimulation, IV ketamine infusions — specialist referral required.

Chronic Post-Burn Pain

• Unique features: pruritus (often as troublesome as pain), contracture-related pain, hypertrophic scarring, neuropathic pain in healed and grafted areas.
• Management: moisturisers, antihistamines (for pruritus), gabapentinoids (for neuropathic pain), amitriptyline, physiotherapy and pressure garments, psychological support.
• Australia has dedicated burns units in each state (e.g., Royal North Shore, Alfred Hospital, Royal Brisbane) with multidisciplinary pain services.

Diagnostic Criteria for CPSP

According to the IASP classification and ICD-11 criteria:

• Pain that developed or increased in intensity after a surgical procedure or tissue trauma.
• Pain of at least 3 months' duration.
• Pain localised to the surgical/trauma site, a referred region, or a dermatome related to the surgery/trauma.
• Other causes of pain excluded (e.g., infection, malignancy, pre-existing pain condition recurrence).

Identifying the Neuropathic Component

Neuropathic pain features are present in 30–70% of CPSP patients. Recognition is crucial because neuropathic pain responds to specific drug classes (gabapentinoids, SNRIs, TCAs) and does not respond reliably to simple analgesia or opioids alone.

Psychological Screening

• Pain Catastrophising Scale (PCS): scores ≥30 indicate high catastrophising; predicts poor analgesic response and CPSP development.
• DASS-21 (Depression, Anxiety and Stress Scale): routinely used in Australian pain clinics.
• PTSD Checklist (PCL-5): essential in posttraumatic pain and post-amputation populations.
• Örebro Musculoskeletal Pain Questionnaire: predicts long-term disability and work absence after musculoskeletal trauma.

Investigations in CPSP and chronic posttraumatic pain serve to exclude ongoing pathology, confirm or characterise neuropathic mechanisms, and guide interventional strategies.

Identifying patients at high risk of developing CPSP before surgery or early after trauma enables targeted preventive interventions.

Empirical therapy for established CPSP and chronic posttraumatic pain follows a multimodal, mechanism-based approach. The WHO analgesic ladder is less useful in this context; instead, treatment targets the predominant pain mechanism (nociceptive, neuropathic, or mixed) and addresses biopsychosocial contributors.

Step 1 — Foundation Therapies

Step 2 — Second-Line and Adjunctive Agents

Directed therapy targets the predominant pain mechanism identified through clinical assessment, validated screening tools, and response to empirical treatment.

Neuropathic Pain-Directed Therapy

Interventional Therapies

Interventional procedures should be considered when ≥4–6 weeks of optimised pharmacotherapy has failed or when a targetable nerve lesion is identified. All require specialist referral.

Multidisciplinary Pain Management

The gold standard for persistent CPSP and chronic posttraumatic pain is a multidisciplinary program combining:

• Pharmacological: Mechanism-based drug selection (see above).
• Physical: Graded exercise therapy, mirror therapy, desensitisation, functional restoration, aquatic therapy.
• Psychological: Cognitive-behavioural therapy (CBT), acceptance and commitment therapy (ACT), pain neuroscience education, mindfulness-based stress reduction (MBSR), EMDR (for PTSD-related pain).
• Interventional: As above, when indicated.
• Social: Occupational therapy, return-to-work programs, peer support, carer education.

Chronic pain management requires regular, structured monitoring to assess treatment efficacy, detect adverse effects, and ensure ongoing alignment with functional goals.

Monitoring Framework

Key Monitoring Measures

1. 1. Schug SA, Lavand'homme P, Barke A, et al. The IASP classification of chronic pain for ICD-11: chronic postsurgical or posttraumatic pain. Pain. 2019;160(1):45–52.
2. 2. Katz J, Seltzer Z. Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Rev Neurother. 2009;9(5):723–744.
3. 3. Richebé P, Capdevila X, Rivat C. Persistent postsurgical pain: risk factors and prevention. Anesth Analg. 2018;126(5):1739–1746.
4. 4. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367(9522):1618–1625.
5. 5. Flor H, Nikolajsen L, Staehelin Jensen T. Phantom limb pain: a case of maladaptive CNS plasticity? Nat Rev Neurosci. 2006;7(11):873–881.
6. 6. Weeks SR, Anderson-Barnes VC, Tsao JW. Phantom limb pain: theories and therapies. Neurologist. 2010;16(5):277–286.
7. 7. Moseley GL, Flor H. Targeting cortical representations in the treatment of chronic pain: a review. Neurorehabil Neural Repair. 2012;26(6):646–652.
8. 8. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173.
9. 9. Australian Institute of Health and Welfare (AIHW). Chronic pain in Australia. Cat. no. PHE 294. Canberra: AIHW; 2023.
10. 10. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
11. 11. Harden RN, Bruehl S, Perez RSGM, et al. Validation of proposed diagnostic criteria (the “Budapest Criteria”) for complex regional pain syndrome. Pain. 2010;150(2):268–274.
12. 12. Deloitte Access Economics. The cost of pain in Australia. Report prepared for Painaustralia. Sydney: Deloitte; 2019.
13. 13. Nicholas MK, Blyth FC. Are self-management strategies effective in chronic pain treatment? Pain Manag. 2016;6(1):75–88.
14. 14. Royal Australian College of General Practitioners (RACGP). Prescription opioid guide: supporting safe prescribing in general practice. East Melbourne: RACGP; 2023.
15. 15. Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc. 2015;90(4):532–545.